000			03047cam a2200409Ii 4500
001			95305
003			ES-MaUEC
005			20230102112657.0
006			m o d
007			cr cnu|||unuuu
008			170203s2017 sz ob 000 0 eng d
020			_a3034809778 _q(electronic bk.)
020			_a9783034809771 _q(electronic bk.)
020			_z3034809751
020			_z9783034809757 _q(print)
035			_a(OCoLC)971245840 _z(OCoLC)971588235 _z(OCoLC)971969580 _z(OCoLC)972106550 _z(OCoLC)972210467 _z(OCoLC)972427783 _z(OCoLC)972574495 _z(OCoLC)981773046 _z(OCoLC)1005831305 _z(OCoLC)1012092540
040			_aN$T _cN$T _dGW5XE _dEBLCP _dN$T _dIDEBK _dYDX _dOCLCF _dNJR _dUAB _dCOO _dIOG _dAZU _dUPM _dESU _dZ5A _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dVT2 _dU3W _dES-MaUEC _bspa
050		4	_aRC858.C95 _bT743 2017 EB
245	0	0	_aTreatment of cystic fibrosis and other rare lung diseases _cArata Azuma, Michael S. Schechter, editors.
264		1	_aSwitzerland _bSpringer _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aMilestones in drug therapy _x2296-6056
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
504			_aIncluye referencias bibliográficas
505	0		_aPart I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
520	3		_aThis volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
650		7	_aFibrosis quística _2embne _0(OCoLC)fst00886196 _0 _9146917
700	1		_aAzuma, Arata, _eeditor literario
700	1		_aSchechter, Michael S., _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-0348-0977-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017B
998			_b02/2018 _dz _e- _zSI
999			_c95305 _d95305 _x1